Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Recurrent or Refractory Multiple Myeloma
Commercial Sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Summary
This trial has one experimental arm split into two phases. In Phase 1, participants will receive EMB-06 once weekly (intravenously) at different ascending dose levels. In Phase 2, participants will receive EMB-06 once weekly (intravenously) at a dose level (RP2D).